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Abstract
Background: In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability,
pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after
infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; registered 19 August 2010).
AAB-003 was developed by modifying bapineuzumab to reduce Fc-receptor-mediated effector function as a
strategy to reduce the removal of amyloid from vessel walls associated with amyloid-related imaging abnormalities
with edema/effusions (ARIA-E) without diminishing overall amyloid clearance.
Methods: Eighty-eight patients with AD received up to three infusions of AAB-003 (or placebo) 13 weeks apart at
doses of 0.5, 1, 2, 4 or 8 mg/kg in the FIH trial. Dose escalation was based on safety data reviews using a Bayesian
escalation algorithm. Subjects who completed the FIH study were permitted to enter a 1-year open-label extension
trial with four additional intravenous infusions of AAB-003 (NCT01369225; registered 10 May 2011).
Results: Dose-dependent increases in plasma amyloid β and AAB-003 were observed. No significant changes
in cerebral spinal fluid biomarkers were observed. Pharmacokinetics elimination half-life (21–28 days) clearance
and volume of distribution values were consistent across dose groups indicating linearity. ARIA-E was the most
notable safety finding detected by magnetic resonance imaging (MRI) at 8 mg/kg in two patients. Three cases of
microhemorrhage were observed. No new safety findings or MRI abnormalities were observed for the 52 subjects
who received AAB-003 in the extension trial.
Conclusion: Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was
safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to
moderate AD. Asymptomatic and resolvable ARIA-E was observed after the first or second infusion of AAB-003,
similar to bapineuzumab. The AAB-003 dose at which ARIA-E was observed was higher compared to
bapineuzumab, supporting the hypothesis that reducing Fc-receptor effector function may reduce the ARIA
associated with monoclonal antibodies targeting cerebral amyloid.
Keywords: Alzheimer's disease, Pharmacokinetics, Monoclonal antibody, Humans, Safety, Immunotherapy, ARIA
* Correspondence: marielle.delnomdedieu@pfizer.com
1Pfizer Neuroscience Research Unit, Cambridge, MA, USA
Full list of author information is available at the end of the article
© 2016 Delnomdedieu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Delnomdedieu et al. Alzheimer's Research & Therapy  (2016) 8:12 
DOI 10.1186/s13195-016-0177-y
Background
To date, phase 3 immunotherapy trials with humanized
monoclonal antibodies (mAb) targeting cerebral amyloid
in patients with mild to moderate Alzheimer’s disease
(AD) have not shown significant improvements in cogni-
tive or functional outcomes [1, 2]. Treatment-related differ-
ences in biomarkers, particularly those in apolipoprotein
(APO)ε4 carriers, and reductions in brain amyloid signal
by positron emission tomography (PET) imaging indicate
mAb-induced central pharmacology [3]. However, these
compounds may not have targeted the pertinent amyloid-β
(Aβ) species, been given in high enough doses, or may have
been administered too late in the progression of AD [2, 4].
The benefits from amyloid immunotherapy may therefore
only be realized by introducing these agents much earlier
in the course of the disease before significant neurodegen-
eration is manifest [5].
The incidence of most adverse events in the anti-
amyloid mAb trials was comparable between active- and
placebo-treated groups and, in general, the compounds
were safe and well tolerated [1, 2]. An exception is the
observation for some mAbs of abnormalities observed
on magnetic resonance imaging (MRI) during safety
monitoring [6–9]. The MRI findings, typically identified
between the first and third intravenous infusions, were
observed on T2-weighted fluid-attenuation inversion re-
covery (FLAIR) sequences and were initially character-
ized as vasogenic edema. To more accurately categorize
these observations, an expert working group developed
the term amyloid-related imaging abnormalities (ARIA)
to encompass parenchymal vasogenic edema and sulcal
effusions (ARIA-E) and also potential abnormalities
observed on GRE/T2* sequences indicative of micro-
hemorrhages and hemosiderosis (ARIA-H) [10].
The incidence of ARIA-E observed in two bapineuzu-
mab phase 3 trials was 15.3 % in the APOε4 carrier study
(11.4 % for heterozygotes; 27.3 % for homozygotes at 0.5
mg/kg) and 4.2 % in the noncarrier study (1 mg/kg),
respectively. One patient in the placebo group (0.2 %) ex-
perienced ARIA-E during each study. On average in these
trials, the incidence of asymptomatic ARIA-E among sub-
jects ranged from 45 to 85 % [1]. It is postulated that
ARIA is related to an increase in amyloid clearance from
cerebral vessels and plaques leading to ARIA-E (vasogenic
edema) and microhemorrhage [11]. Although it occurs
spontaneously, ARIA is observed more frequently with
amyloid-lowering therapy, particularly with antiamyloid
immunotherapy [12].
Several lines of evidence support the concept that
reduction of Fc-receptor-mediated effector function rep-
resents a potential strategy to reduce rapid removal of
amyloid from vessel walls without diminishing overall
amyloid clearance [13, 14]. In preclinical models, these
substitutions reduced antibody-dependent cell-mediated
cytotoxicity and complement activation compared to
bapineuzumab while still retaining its capacity in amyl-
oid plaque clearance [13]. Such a strategy may improve
the safety profile of bapineuzumab (AAB-001), a mAb
directed at the N-terminal sequence of Aβ. To achieve
this Fc effector function reduction, AAB-003 was devel-
oped by introducing a three amino acid mutation in the
lower hinge region of bapineuzumab monoclonal anti-
bodies, resulting in the reduced binding of AAB-003 to
FcγR compared to bapineuzumab, as well as significantly
reduced binding to complement C1q and diminished
antibody dependent cellular cytotoxicity (unpublished
Janssen data). The AAB-003 pharmacologic profile sug-
gested a reduced risk for ARIA and thereby allowed a
higher dose to be assessed compared to bapineuzumab.
The objectives of the First-In-Human (FIH) study were
to investigate the safety, tolerability and pharmacokinet-
ics of multiple doses of AAB-003 in subjects with mild
to moderate AD. Five doses were studied, with up to
three infusions. An important aim was to efficiently es-
tablish whether AAB-003 had a better safety profile than
bapineuzumab. This study combined single ascending
dose (SAD) and multiple ascending dose (MAD) ap-
proaches in one adaptive study in which dose escalation
and subject allocation were performed based on real-
time data capture and prespecified decision rules. The
unique design allocated most of the subjects to the high-
est dose with an acceptable safety profile, while reducing
the number of subjects exposed to doses with excessive
ARIA-E rates.
Long-term safety and tolerability data were obtained
during a 52-week open-label extension (OLE).
Methods
The FIH study was a randomized, double-blind, placebo-
controlled, safety, tolerability, and pharmacokinetic (PK)
adaptive design, dose-escalation study of AAB-003 in
male and female subjects with mild to moderate AD
(NCT01193608). Five AAB-003 dose levels were studied
in escalating fashion: 0.5, 1, 2, 4 and 8 mg/kg. In each
dose cohort, AAB-003 (or placebo) was administered via
a 1-hour intravenous (IV) infusion once every 13 weeks
for a total of three infusions (day 1, week 13 and week
26). The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki and was
in compliance with Good Clinical Practice. A central
investigational review board (IRB; Schulman Associates
IRB, Cincinnati, Ohio, www.sairb.com) and individual
site institutional review boards reviewed and provided
approval for the protocols as well as informed consent
forms. All subjects provided informed consent and con-
sent for publication.
Subjects who successfully completed the FIH study and
continued to meet study inclusion criteria were permitted
Delnomdedieu et al. Alzheimer's Research & Therapy  (2016) 8:12 Page 2 of 10
to enter the 52-week OLE and receive four additional IV in-
fusions of AAB-003 given 13 weeks apart (NCT01369225).
Subjects who received active treatment in the FIH re-
mained on the same dose in the OLE study. Subjects who
received placebo during the FIH study received AAB-003
in the OLE at a dose based on their dose cohort in
the FIH study.
Studies were conducted at 10 centers in the USA and
6 in Korea (see Additional file 1).
Patients between the ages of 50 and 89 years inclusive
with a diagnosis of probable AD according to National
Institute of Neurological and Communicative Disorders
Association criteria were eligible for enrollment. Other re-
quirements included a Mini-Mental State Exam (MMSE)
score of 16 to 26 inclusive (12 or greater for OLE), Rosen
Modified Hachinski Ischemic score of <4, and an MRI
consistent with the diagnosis of AD. Additional study cri-
teria can be found at www.clinicaltrials.gov. Patients with
more than one microhemorrhage or lacunar infarct or
evidence of a single prior infarct >1 cm3, evidence of a
cerebral contusion, encephalomalacia, space occupying
lesions, or brain tumors were excluded. Patients receiving
approved symptomatic treatments for AD were allowed in
the FIH study if on stable doses for 4 months prior to
screening.
An adaptive dose finding design was employed. The
initial cohort size in the FIH study was 4 to 8 subjects
(3:1 active:placebo ratio) starting at a 0.5 mg/kg dose of
AAB-003. Further increases were approved by an external
Data Monitoring Committee (DMC) using a Bayesian es-
calation algorithm, after review of safety and tolerability
data [15]. The algorithm used real-time emerging data on
safety endpoints, ARIA-E, and dose-limiting adverse
events other than ARIA-E to select the dose for the next
cohort. The decision rules to escalate/de-escalate/stay
were based on Bayesian posterior probabilities that
the proportion of ARIA-E was ≤5 % and the propor-
tion of dose-limiting adverse events other than ARIA-E
was ≤30 %. Randomization was to continue until 80 sub-
jects were enrolled (with ~60 allocated to active) or at
least 24 subjects were allocated to active treatment at that
maximum dose.
The study rules stated that if two or more cases of
ARIA-E were observed within a cohort size of 4 to 8, the
dose was to be de-escalated and 4 additional subjects
allocated to the reduced dose. Further dose allocation
was to be reassessed using the Bayesian algorithm and
the additional safety experience at the reduced dose
(symptomatic case counted as 2). One asymptomatic
case of ARIA-E would have led to maintaining the
current dose and allocating another 4 subjects to it;
further dose allocation was to be reassessed based on
observed safety. To generate additional FIH safety and
biomarker data, 12 more subjects (10 active, 2 placebo)
were enrolled at the 2 or 4 mg/kg doses once either dose
was deemed safe per Bayesian escalation algorithm. Pa-
tients who completed the FIH without drug-related ser-
ious adverse events (SAE) and met inclusion criteria
were permitted to enter a 52-week OLE study to provide
longer term safety and tolerability data.
Safety
Safety assessments, including adverse event (AE) reports,
physical and neurological examinations, suicidality assess-
ments, 12-lead electrocardiograms (ECGs), and laboratory
determinations, were performed at screening, baseline and
at predetermined visits for both FIH and OLE studies.
Vital signs were obtained at all visits. During and after in-
fusion of study drug, patients were observed for 6 hours.
Sitting blood pressure and pulse were measured at 15-min
intervals during the infusion, for the first hour after infu-
sion and every 30 min thereafter. Based on the bapineuzu-
mab clinical trial experience, FIH patients were monitored
for MRI brain abnormalities (ARIA-E, ARIA-H) at screen-
ing (baseline scan), 3 and 6 weeks after the first and sec-
ond infusions, and 6 weeks following the third and last
infusion [6, 16]. No MRI volumetric analysis was per-
formed, nor was amyloid PET imaging performed. In the
OLE study, MRIs were obtained 6 weeks after each infu-
sion and at week 52. The study treatment duration was 39
weeks for the FIH and 52 weeks for the OLE and included
a final safety follow-up visit. All subjects who received an
infusion of study medication (including partial infusions)
were included in the safety analysis population.
PK and PD in the FIH Study
Serum AAB-003, Plasma Aβx-40 and anti-AAB-003 antibodies
Standard, model-independent, noncompartmental PK
methods were used to characterize the serum concentra-
tion–time profiles of AAB-003 and plasma Aβx-40. Standard
PK parameters were derived from the concentration–time
data following AAB-003 administration: peak concentration
(Cmax), time to Cmax (Tmax), total area under the concentra-
tion–time curve to 13 weeks (AUC0-13weeks) and infinity
(AUCinf ), apparent terminal phase elimination half-life
(t1/2), systemic clearance (CL) and steady-state volume
of distribution (Vss). Blood samples for serum AAB-003
PK evaluations in the FIH study were collected on day 1
(predose, 1 hour (end of infusion), 1.5, 2, 4 and 6 hours
postinfusion start), day 2 (24 hours postinfusion start),
weeks 1, 3, 6, 10, 13 (predose, 1 hour (end of infusion)),
week 19, week 26 (predose, 1 hour (end of infusion), 1.5,
2, 4, 6, and 24 hours postinfusion start), and weeks
32 and 39.
Blood samples for exploratory analysis of plasma Aβx-40
were collected from all patients on day 1 (predose, 1 hour
(end of infusion) and 2 hours postinfusion start), day 2,
weeks 1, 6, and 13 (predose, 1 hour (end of infusion) and
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2 hours postinfusion start), week 19, week 26 (predose, 1
hour (end of infusion) and 2 hours postinfusion start),
week 32 and week 39. Intensive blood sampling was im-
plemented after the first and third doses in the FIH study
to evaluate AAB-003 PK and plasma Aβx-40 after a single
dose and at steady state. In the OLE study, PK and
pharmacodynamics (PD) samples were collected less fre-
quently. Therefore, PK and PD data presentation and dis-
cussion is limited to the FIH study. Serum samples for
anti-AAB-003 antibodies were collected prior to dosing in
the FIH study at weeks 13, 26 and 39.
The PK/PD analysis population included all randomized
subjects who received at least one infusion of study medi-
cation and had at least one postdose PK/PD assessment.
Cerebrospinal Fluid Biomarkers in the FIH study
Cerebrospinal fluid (CSF) samples were collected at
baseline and at approximately week 32 (or early with-
drawal) from a subset of subjects who provided consent
from the 2 mg/kg, 4 mg/kg and 8 mg/kg cohorts in the
FIH. CSF samples were analyzed for Aβx-40, Aβx-42, t-tau,
p-tau and AAB-003 concentrations. CSF sample collection
was only made mandatory in the FIH after reaching the
highest dose of 8 mg/kg. No more than 5 patients pro-
vided consent for CSF collection at week 45 of the OLE.
Due to this small number of CSF samples, CSF exposure
and biomarker data are limited to the FIH.
The CSF analysis population consisted of subjects in
the 8 mg/kg AAB-003 cohort who provided sufficient
CSF samples at baseline and 32 weeks to allow for the
assaying of both samples, and who had no ARIA-E oc-
currence. There were insufficient numbers of subjects
on AAB-003 in the 2 mg/kg and 4 mg/kg cohorts for
group analysis. Placebo data from the 2 mg/kg and 4
mg/kg cohorts were included in the analysis. The change
from baseline for each of the CSF biomarkers in the 8
mg/kg AAB-003 cohort was analyzed using one-sample
paired t-test. To compare AAB-003 and placebo-treated
subjects, an exploratory analysis using a mixed model
with fixed effects for treatment, center, age, baseline
MMSE category, baseline biomarker value and random
subject effect was also performed.
Assay Methods
All assays were conducted using validated methodologies
developed in compliance with Janssen AI Bioanalytical
Development operating procedures and documented in
method validation reports. Enzyme-linked immunosorbent
assay methodologies were used to measure AAB-003 and
anti-AAB-003 antibody concentrations in serum and t-tau
and p-tau concentrations in CSF (Innotest, Fujirebio). CSF
AAB-003 concentrations were determined using an
electrochemiluminescence methodology. Plasma Aβx-40
samples, CSF Aβx-40 and Aβx-42 concentrations were
determined by Meso Scale Discovery technology and plate
reader.
Efficacy Endpoints in the FIH and OLE studies
Exploratory efficacy of AAB-003 was evaluated using the
Alzheimer's Disease Assessment Scale-Cognitive Sub-
scale (ADAS-Cog), Disability Assessment for Dementia
(DAD), Neuropsychiatric Inventory (NPI), Clinical De-
mentia Rating (CDR) and MMSE. These endpoints were
summarized by treatment group based on a full analysis
population set consisting of all randomized patients who
received at least one infusion of study medication.
Results
Patients
A total of 174 patients were screened for participation in
the FIH study of which 88 were confirmed as eligible,
randomized to treatment and constituted the safety
population (Fig. 1). Patient ages ranged from 51 to 88
years and the mean ages across treatment groups were
comparable and ranged from 64.5 to 71.5 years (Table 1).
Subjects were predominantly White (47 %) or Asian
(43 %) and to a lesser extent Black (10 %). None of the
participating patients were known to have any illness at
baseline that might interfere with the activity of AAB-003
or interpretation of the study results. Many enrolled pa-
tients had a history of chronic, stable medical conditions
that did not interfere with the conduct of this study. All
patients, except for 4, took at least one concomitant medi-
cation. The most commonly reported concomitant medi-
cations were donepezil (39 %), memantine (32 %) and
acetylsalicylic acid (35 %). Of the 72 subjects who com-
pleted the FIH study, 52 enrolled in the OLE (19 males
and 33 females). Patients in the OLE were predominantly
White or Asian and mostly ranged in age from 52 to 74
years (Table 2).
Safety
Of the 69 patients who received AAB-003 in the FIH
study, 42 (61 %) reported a treatment-emergent adverse
event (TEAE) (Table 3). Of the 19 patients treated with
placebo, 12 (63 %) reported a TEAE. There were 14 dis-
continuations from the FIH study: 9 no longer willing to
participate, 3 lost to follow-up, 1 travel inconvenience,
and 1 cerebral microhemorrhage. The most com-
monly reported all-causality TEAEs for combined
AAB-003-treated subjects were decreased appetite (7
patients, 10.1 %) followed by dizziness and headache
(5 patients each, 7.2 %). Two patients who received pla-
cebo reported dizziness (10.5 %) and 1 reported headache
(5.3 %). The most commonly reported treatment-related
TEAE was ARIA-H (3 patients, 4.3 %), ARIA-E (n = 2,
2.9 %) and nausea (n = 2, 2.9 %). The majority of TEAEs
were mild to moderate in severity; no deaths were reported.
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At the highest dose, the frequency and severity of TEAEs
tended to increase. The more severe treatment-related AEs
(6 moderate, 1 severe and 1 very severe) at 8 mg/kg were
predominantly related to the central nervous system:
ARIA-E (n = 2, 8.3 %), ARIA-H (n = 2; 8.3 %), head-
ache (n = 1, 4.2 %), insomnia (n = 1, 4.2 %), dizziness
(n = 1, 4.2 %), confusional state (n = 1, 4.2 %) and impaired
self-care (n = 1, 4.2 %). Of the 9 SAEs reported for 9
patients in the FIH, 5 were treatment related: 2 ARIA-E
and 3 ARIA-H (one ARIA-H reported as an SAE was not
reported as an AE). None of the unrelated SAEs were
concurrent with ARIA findings.
Asymptomatic ARIA-E was identified in 2 (8.3 %) of
the 24 patients who received 8 mg/kg. The first case was
detected at the week 6 scheduled MRI scan and the study
drug was immediately discontinued, as per protocol. An
Table 1 Demographic and baseline characteristics—First-In-Human
Number of subjects AAB-003
0.5 mg/kg (N = 6) 1 mg/kg (N = 6) 2 mg/kg (N = 16) 4 mg/kg (N = 17) 8 mg/kg (N = 24) Placebo (N = 19)
Age (years), mean (SD) 64.5 (6.4) 67.2 (7.4) 70.7 (10.8) 71.5 (8.8) 64.5 (7.6) 71.1 (7.6)
Sex, n
Male 2 3 2 8 10 12
Female 4 3 14 9 14 7
Ethnicity, n
White 4 3 5 6 12 11
Black 2 2 1 0 1 3
Asian 0 1 10 11 11 5
Weight (kg) mean (SD) 70.9 (13.4) 69.8 (18.4) 58.0 (10.7) 64.1 (10.5) 70.8 (17.5) 74.1 (21.8)
MMSE score, mean (SD) 22.7 (1.37) 22.5 (2.43) 20.8 (3.71) 20.1 (3.00) 21.2 (2.82) 21.2 (3.78)
MMSE Mini-Mental State Exam, SD Standard deviation
Fig. 1 Patient disposition. FIH First-In-Human, OLE Open label extension
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increased area of ARIA-E was noted in a subsequent MRI
scan 22 days later. Thereafter, ARIA-E showed progressive
resolution on MRI at weeks 16 and 19, with complete
resolution reported on MRI at week 39. The subject was
ApoE4 negative (ε3/ε3). The second case was identified on
MRI at week 16 (3 weeks after second infusion) and the
study drug was discontinued. Thereafter, an increased
area of ARIA-E was observed on MRI at week 19. Com-
plete resolution was reported on MRI at week 32. The
subject was ApoE4 positive (ε3/ε4). There was no clear
link between ARIA-E and ApoE4 carrier status in this
study.
A total of 4 asymptomatic ARIA-H cases were ob-
served: 1 (6.3 %) in the 2 mg/kg treatment group and 3
(12.5 %) in the 8 mg/kg treatment group. The patient in
the 2 mg/kg treatment group entered the trial with a
single ARIA-H which increased to three lesions post-
treatment initiation. One case at 8 mg/kg was concomi-
tant with the ARIA-E at week 6 described above; it
remained unchanged on subsequent MRIs. The second
Table 2 Demographic and baseline characteristics—52-week Open Label Extension
Number of subjects AAB-003
0.5 mg/kg (N = 6) 1 mg/kg (N = 3) 2 mg/kg (N = 12) 4 mg/kg (N = 10) 8 mg/kg (N = 12) Placebo to AAB-003 (N = 9)*
Age (years), mean (SD) 65.2 (6.5) 63.0 (7.8) 68.8 (10.6) 71.3 (8.8) 60.7 (5.8) 71.7 (7.9)
Sex, n
Male 2 1 2 5 4 5
Female 4 2 10 5 8 4
Ethnicity n
White 4 1 2 1 3 4
Black 2 2 0 0 2 0
Asian 0 0 10 9 7 5
Weight (kg), mean (SD) 71.8 (13.7) 80.0 (26.2) 54.0 (8) 65.0 (12.8) 69.9 (18.0) 66.7 (22.3)
MMSE, mean (SD) 24.7 (1.86) 21.0 (4.36) 19.3 (5.05) 18.5 (4.86) 21.3 (5.40) 18.9 (5.64)
*Number of placebo subjects who transitioned to AAB-003 in the open label extension: 1 at 0.5 mg/kg, 1 at 1 mg/kg, 3 at 2 mg/kg, 1 at 4 mg/kg, and 3 at 8 mg/kg.
MMSE Mini-Mental State Exam, SD Standard deviation
Table 3 Treatment-emergent adverse events occurring in ≥2 patients in any treatment group––First In Human
Adverse event AAB-003
0.5 mg/kg (N = 6) 1 mg/kg (N = 6) 2 mg/kg (N = 16) 4 mg/kg (N = 17) 8 mg/kg (N = 24) Placebo (N = 19)
n (%) n (%) n (%) n (%) n (%) n (%)
Anxiety 0 0 2 (12.5) 0 0 2 (10.5)
ARIA-E 0 0 0 0 2 (8.3) 0
ARIA-H 0 0 1 (6.3) 0 2 (8.3)* 0
Back pain 0 0 2 (12.5) 0 1 (4.2) 0
Decreased appetite 0 2 (33.3) 3 (18.8) 2 (11.8) 0 0
Dizziness 0 0 2 (12.5) 2 (11.8) 1 (4.2) 2 (10.5)
Fall 0 0 2 (12.5) 1 (5.9) 0 1 (5.3)
Gait disturbance 0 0 1 (6.3) 2 (11.8) 0 1 (5.3)
Headache 1 (16.7) 1 (16.7) 0 2 (11.8) 1 (4.2) 1 (5.3)
Nasopharyngitis 1 (16.7) 0 1 (6.3) 0 2 (8.3) 1 (5.3)
Nausea 1 (16.7) 0 1 (6.3) 0 2 (8.3) 1 (5.3)
Sinusitis 0 1 (16.7) 0 0 2 (8.3) 0
Urinary tract infection 1 (16.7) 0 1 (6.3) 0 2 (8.3) 0
Weight increased 0 0 0 0 2 (8.3) 0
Vomiting 0 0 0 1 (5.9) 2 (8.3) 1 (5.3)
*One case was not reported as an adverse event (ARIA-H incidence based on central magnetic resonance imaging reporting was 12.5 %). ARIA-E Amyloid-related
imaging abnormalities with edema/effusions, ARIA-H Amyloid-related imaging abnormalities indicative of microhemorrhages and hemosiderosis
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8 mg/kg case involved a single ARIA-H detected on
the scheduled MRI at week 16 following two doses of
study drug. An additional ARIA-H was reported on MRI
at week 32. The study drug was not stopped and the event
outcome was not considered resolved at the end of the
study. The third ARIA-H was observed at the week 32
visit and reported as an SAE (but not as an AE).
Of the 52 patients who received AAB-003 in the OLE
study, 40 (75 %) reported a TEAE (Table 4), the majority
of which were mild to moderate in severity. No deaths
were reported. There were 9 discontinuations (17 %), none
considered related to the study drug. The most commonly
reported all-causality TEAEs were depression (n = 6, 11 %)
followed by urinary tract infection (n = 5, 9 %). Treatment-
related TEAEs were reported by 12 patients (23 %), 6 of
whom were in the 8 mg/kg treatment group. All other
treatment groups had similar number of treatment-related
TEAEs. No findings of ARIA-E or ARIA-H were identified
in the OLE. Of the 11 SAEs reported for 8 patients in the
OLE, none were treatment related.
For both the FIH and OLE, there was no evidence
of clinically significant changes in laboratory tests, vital
sign measurements, physical examination, neurologic
examination, or ECG results.
PK and PD for the FIH
Mean AAB-003 serum concentration versus time curves
for each dose are presented in Fig. 2. AAB-003 serum
Cmax and AUCinf values after single doses increased with
dose in a roughly dose-proportional fashion within the
0.5–8 mg/kg dose range. The t1/2 was similar across all
dose groups and was approximately 21–28 days. The
median Tmax values after the infusion ranged from 1.5–
4.0 hours across doses. AAB-003 clearance (CL) and vol-
ume of distribution (Vss) values were consistent across
all dose groups suggesting linear PK (Table 5). The mean
(%CV) CSF AAB-003 concentration following the 8 mg/kg
dose was 79.16 (67) ng/ml.
Following AAB-003 infusion, a dose-dependent increase
in plasma Aβx-40 was observed across the entire dose
range. The median time to maximum plasma Aβx-40
increased from approximately 24 hours at lower doses
(0.5–2 mg/kg) to approximately 164 hours at higher doses
(4–8 mg/kg) (Table 6). The t1/2 for plasma Aβx-40, when
estimated, was approximately 30 days. No anti-AAB-003
antibodies were observed in the FIH study.
CSF biomarkers (CSF Aβx-40, Aβx-42, tau, p-tau)
Results of a one-sample paired t-test used to compare
the change in CSF biomarkers of patients in the 8 mg/kg
treatment group at baseline and at week 32 are detailed
in Table 7. The change from baseline in the 8 mg/kg
treatment group was (in pg/ml): 113.53 for Aβx-40
(placebo = 348.64, n = 5), 48.85 for Aβx-42 (placebo = 24.04),
–15.26 for tau (placebo = 67.94), and 1.23 for p-tau (pla-
cebo = 1.92). The within-group change from baseline to
week 32 for all CSF biomarkers—Aβx-40, Aβx-42, tau
and p-tau—in the 8 mg/kg treatment group did not dem-
onstrate statistical significance.
The mixed model analysis showed the difference in
change from baseline to week 32 between the 8 mg/kg
treatment and placebo groups was not statistically sig-
nificant (at level 0.05) for any CSF biomarkers.
Exploratory efficacy endpoints for the FIH and extension
study
Neither study was designed to compare between-
treatment groups or to assess the overall efficacy of AAB-
003. Efficacy evaluations were thus limited to calculation
of the mean change from baseline of each exploratory effi-
cacy endpoint calculated at weeks 13, 26 and 39 for the
FIH and at weeks 13, 26, 39 and 52 for the OLE. Based on
inspection of the mean changes from baseline in ADAS-
Cog, DAD, NPI, CDR and MMSE among the treatment
groups, there was no clear indication of drug effect over
Table 4 Treatment-emergent adverse events occurring in ≥2 patients in any treatment group—52-week open label extension
Adverse event AAB-003
0.5 mg/kg to 0.5 mg/kg
(N = 6)
1 mg/kg to 1 mg/kg
(N = 3)
2 mg/kg to 2 mg/kg
(N = 12)
4 mg/kg to 4 mg/kg
(N = 10)




n (%) n (%) n (%) n (%) n (%) n (%)
Anxiety 0 0 2 (16.7) 0 1 (8.3) 0
Back pain 0 0 2 (16.7) 0 0 1 (11.1)
Depression 0 0 1 (8.3) 0 3 (25) 2 (22.2)
Dizziness 0 0 1 (8.3) 0 2 (16.7) 1 (11.1)
Contusion 0 0 0 0 2 (16.7) 0
Fall 1 (16.7) 2 (66.7) 0 0 1 (8.3) 0
Pollakiuria 0 0 2 (16.7) 0 0 0
*Number of placebo subjects who transitioned to AAB-003 in the open label extension: 1 at 0.5 mg/kg, 1 at 1 mg/kg, 3 at 2 mg/kg, 1 at 4 mg/kg, and 3 at 8 mg/kg
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time in either study. This is anticipated as the number of
subjects is small in both studies.
Discussion
During the 39-week FIH study, the only notable safety
findings were observed by MRI at 8 mg/kg and included
two cases of asymptomatic ARIA-E observed at week 6
and week 16 (both resolved by week 32), and three new
microhemorrhages (confirmed by being observed on
more than one MRI scan). Based upon all laboratory re-
sults, ECG data, integrated assessments of AE, SAE and
MRI findings, AAB-003 was found to be safe and well
tolerated up to 8 mg/kg in the FIH study. In the 52-
week OLE no new safety or tolerability findings emerged
and no MRI findings of ARIA-E or ARIA-H were re-
ported at any dose. The absence of ARIA-E in the OLE,
particularly for the 8 mg/kg dose, is consistent with the
bapineuzumab experience showing ARIA-E most likely
to appear after the first or second infusion of drug.
The FIH study was also designed to assess the concept
that modifying bapineuzumab to reduce Fc-receptor-
mediated effector function would reduce the risk for
ARIA-E and microhemorrhage. The results from this
FIH study appear to support that concept: the dose
Fig. 2 Mean serum AAB-003 concentrations following initial intravenous infusions of increasing doses of AAB-003
Table 5 Summary of serum AAB-003 pharmacokinetic parameters
Parameters (units) 0.5 mg/kg (N = 6) 1 mg/kg (N = 6) 2 mg/kg (N = 16) 4 mg/kg (N = 17) 8 mg/kg (N = 24)
Cmax (μg/ml) 13.79 (48) 32.05 (33) 58.74 (21) 122.4 (14) 223.7 (28)
Tmax (hours) 1.92 (1.50, 6.05) 4.00 (2.17, 6.02) 1.54 (1.20, 2.12) 1.50 (1.00, 24.0) 3.02 (1.07, 6.00)
AUCinf (μg/hour/ml) 5597 (39) 13060 (18) 25270 (17) 46430 (21) 82140 (23)
t1/2 (days) 27.7 ± 6.99 20.04 ± 8.92 24.45 ± 4.87 21.10 ± 5.20 22.89 ± 4.51
CL (ml/hour/kg) 0.0893 (39) 0.0766 (18) 0.0791 (17) 0.0862 (21) 0.0974 (23)
Vss (ml/kg) 78.44 (38) 59.74 (37) 61.67 (21) 60.44 (26) 75.12 (27)
N: Number of patients with pharmacokinetic parameters on day1 (may be different from number of patients with estimable t1/2). Geometric mean (geometric %CV) for
all except median (range) for Tmax and arithmetic mean ± standard deviation for t1/2. AUCinf Total area under the concentration–time curve to infinity, CL Systemic
clearance, Cmax Observed peak concentration, t1/2 Apparent terminal phase elimination half-life, Tmax Time to peak concentration, Vss Steady-state volume of distribution
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associated with ARIA-E in this trial was 8 and 16 times
higher compared to bapineuzumab in the phase 3 APOε4
carrier and noncarrier studies, respectively [1].
The pharmacokinetics of AAB-003 following IV infu-
sion every 13 weeks were characterized by slow clearance
and low volume of distribution which is typical of mono-
clonal antibodies including bapineuzumab [6]. AAB-003
Cmax and AUCinf values increased in a dose-proportional
fashion with relatively similar CL and Vss values across
the dose groups (0.5–8 mg/kg), suggesting linear pharma-
cokinetics. Accumulation of AAB-003 concentrations was
minimal with every 13-week infusion (data not shown).
Average CSF AAB-003 concentrations at week 32 were
less than 1 % of the observed serum AAB-003 con-
centrations. This is also typical of other monoclonal
antibodies [17]. Similar to bapineuzumab, no anti-AAB-
003 antibodies were observed indicating low AAB-003
immunogenicity.
A dose-dependent increase in plasma Aβx-40 concen-
trations demonstrated peripheral target engagement.
Plasma Aβx-40 levels were similar to those observed after
bapineuzumab administration at comparable doses (Pfizer
Unpublished Data on File). The lack of significant change
in CSF levels of Aβx-40 and Aβx-42, tau and p-tau may be
due to the short duration of therapy (32 weeks) or the
smaller sample size. Further investigation beyond 32
weeks is necessary to accurately delineate the effect of
AAB-003 on CSF biomarker of AD.
By combining sequential SAD and MAD studies into
one adaptive study design, the overall number of patients
and time required to characterize the dose-limiting ad-
verse event of special interest (ARIA-E) was reduced. The
Bayesian algorithm and predefined decision rules effi-
ciently allowed advancement from the lowest dose of 0.5
mg/kg up to the highest dose of 8 mg/kg in smaller cohort
sizes, while allocating the largest number of patients to
the highest dose of 8 mg/kg where ARIA-E emerged. The
use of real-time safety data collection allowed these deci-
sions to be made by the DMC with only brief pauses to
the trial during evaluation. Although not utilized during
the conduct of the study, the predecision rules on dose re-
duction and patient allocation provided clear guidance to
the DMC and study team on how to continue the study
and generate additional information in the event an
unacceptable number of dose-limiting AEs had been
observed.
The limited 39-week duration for the FIH was based
on clinical experience with bapineuzumab indicating
ARIA-E was most likely to occur after the first or second
infusions given 13 weeks apart. Consequently, there are
two limitations to the data provided from the combined
experience from the FIH and 1-year extension trial. First,
the confidence in the true rate of ARIA-E observed at 8
mg/kg, an association with APOε4 status, and the risk
for coincident ARIA-H, are limited by the relatively
small sample size of 24 patients at that dose in the FIH
study. Second, the safety profile of AAB-003 in pa-
tients who experienced ARIA-E and continued to receive
AAB-003 is unknown, since dosing was discontinued, per
protocol, for the two patients with ARIA-E in the FIH
study. Future AAB-003 clinical studies of larger size, along
with a consideration to permit continued dosing of AAB-
003 in patients who experience ARIA-E, would address
these limitations.
Conclusion
The results from the FIH and extension study showed
AAB-003 was safe and well tolerated up to 8 mg/kg for
up to 91 weeks (First-In-Human study and its open label
extension) in patients with mild to moderate AD.
Table 6 Summary of plasma Aβx-40 pharmacokinetic parameters
Parameters (units) Placebo (N = 19) 0.5 mg/kg (N = 6) 1 mg/kg (N = 5) 2 mg/kg (N = 14) 4 mg/kg (N = 16) 8 mg/kg (N = 22)
Cmax (ng/ml) 0.3511 (25) 3.321 (50) 6.959 (29) 8.202 (19) 11.89 (10) 18.03 (19)
Tmax (hours) 168 (0.00, 2540) 24.2 (22.3, 149) 24.0 (24.0, 169) 24.0 (24.0, 170) 166 (24.0, 238) 164 (92.2, 2050)
AUC0-13weeks (ng/hour/ml) 631.6 (23.3) 2647 (31) 6057 (47) 7854 (19) 12,940 (17) 22,820 (25)
t1/2 (days) Not Reported 26.57* 32.14* 30.71 ± 3.23 25.4, 33.5* Not reported
N: Number of patients with pharmacokinetic parameters on Day1 (may be different from number of patients with estimable t1/2. Geometric mean (geometric %CV) for
all except median (range) for Tmax and arithmetic mean ± standard deviation for t1/2. *Individual values for n < 3. AUC0-13weeks Total area under the concentration–time
curve to 13 weeks, Cmax Observed peak concentration, t1/2 Apparent terminal phase elimination half-life, Tmax Time to peak concentration
Table 7 One-sample paired t-test for change from baseline to week 32 of cerebrospinal fluid biomarkers in the 8 mg/kg group
Biomarker Mean change 80 % CI 95 % CI P value
Aβx-40 (pg/ml) 113.53 (–170.30, 397.35) (–339.06, 566.12) 0.599
Aβx-42 (pg/ml) 48.85 (–11.79, 109.48) (–47.84, 145.53) 0.297
Tau (pg/ml) −15.26 (–53.54, 23.02) (–76.30, 45.78) 0.600
P-tau (pg/ml) 1.23 (–1.89, 4.35) (–3.74, 6.21) 0.603
CI Confidence interval
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Asymptomatic and resolvable ARIA-E was observed
after the first or second infusion of AAB-003, which is
similar to bapineuzumab. In contrast, the AAB-003 dose
at which ARIA-E was observed was considerably higher
compared to bapineuzumab, a finding that supports the
hypothesis that reducing Fc-receptor effector function
may reduce the risk of ARIA associated with monoclonal
antibodies targeting cerebral amyloid.
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